1. Home
  2. PSBD vs TENX Comparison

PSBD vs TENX Comparison

Compare PSBD & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Palmer Square Capital BDC Inc.

PSBD

Palmer Square Capital BDC Inc.

HOLD

Current Price

$9.83

Market Cap

325.5M

Sector

N/A

ML Signal

HOLD

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$15.88

Market Cap

317.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PSBD
TENX
Founded
2009
1967
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
325.5M
317.8M
IPO Year
2019
2001

Fundamental Metrics

Financial Performance
Metric
PSBD
TENX
Price
$9.83
$15.88
Analyst Decision
Hold
Strong Buy
Analyst Count
9
3
Target Price
$12.33
$29.67
AVG Volume (30 Days)
204.7K
1.4M
Earning Date
05-06-2026
05-15-2026
Dividend Yield
15.02%
N/A
EPS Growth
N/A
N/A
EPS
1.66
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$6.04
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.34
$5.77
52 Week High
$14.43
$19.40

Technical Indicators

Market Signals
Indicator
PSBD
TENX
Relative Strength Index (RSI) 30.50 58.40
Support Level $9.34 $12.84
Resistance Level $11.08 $16.35
Average True Range (ATR) 0.28 1.28
MACD -0.06 -0.07
Stochastic Oscillator 0.00 48.37

Price Performance

Historical Comparison
PSBD
TENX

About PSBD Palmer Square Capital BDC Inc.

Palmer Square Capital BDC Inc is a financial services company that lends to and invests in corporate debt securities of companies, including small to large private U.S. companies. Their investment objective is to maximize total return, comprised of current income and capital appreciation.

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

Share on Social Networks: